APRIL antibody has passed a registrational test in a rare kidney disease, marking a significant win from its 2018 buyout of ...

The method utilizes Rice’s cytokine “drug factory” and a checkpoint inhibitor drug to do the heavy lifting. They found during testing that the implants could eradicate advanced-stage tumors ...

This innovative approach combines Rice’s cytokine “drug factory” implants with a checkpoint inhibitor drug, showing promising ...

This highly innovative technology promises to unleash the full potential of cytokines in oncology by dramatically increasing the therapeutic index of this class of drugs. We are also interested in ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

With the progress being made in biopharmaceutical technology, there is a significant space for the future growth of targeted cytokine drugs. This offers a good prospect for effectively treating ...

Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...

Research uncovers how P-stalk ribosomes regulate cytokine responses, driving immune evasion in tumors across multiple cancer ...

This highly innovative technology promises to unleash the full potential of cytokines in oncology by dramatically increasing the therapeutic index of this class of drugs. We are also interested in ...